Real-world epidemiology, treatment patterns and disease burden of patients diagnosed with chronic hepatitis B in Taiwan

被引:1
作者
Chien, Hsiu-Ting [1 ]
Su, Tung-Hung [2 ,3 ,4 ]
Huang, Hazel [5 ]
Chiang, Chih-Lin [6 ]
Lin, Fang-Ju [1 ,7 ,8 ]
机构
[1] Natl Taiwan Univ, Grad Inst Clin Pharm, Coll Med, Taipei, Taiwan
[2] Natl Taiwan Univ Hosp, Dept Internal Med, Div Gastroenterol & Hepatol, Taipei, Taiwan
[3] Natl Taiwan Univ, Coll Med, Dept Internal Med, Taipei, Taiwan
[4] Taiwan Univ Hosp, Hepatitis Res Ctr Natl, Taipei, Taiwan
[5] Cerner Enviza, Taipei, Taiwan
[6] Janssen Pharmaceut Johnson & Johnson, Taipei, Taiwan
[7] Natl Taiwan Univ, Coll Med, Sch Pharm, Taipei, Taiwan
[8] Natl Taiwan Univ Hosp, Dept Pharm, Taipei, Taiwan
关键词
chronic hepatitis B; clinical outcomes; economic costs; epidemiology; healthcare resource utilization; VIRUS INFECTION; ASIA-PACIFIC; COMORBIDITIES;
D O I
10.1111/liv.15702
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background and AimsThis study aimed to update the epidemiology, clinical, and economic outcomes of patients diagnosed with chronic hepatitis B (CHB) infection in Taiwan.MethodsThis is a retrospective observational study using claims data from the National Health Insurance Research Database. Cases were identified between 2010 and 2019 using CHB diagnosis codes and claims for alanine aminotransferase laboratory tests or CHB treatment within one year of the first CHB diagnosis. Patient characteristics, epidemiology, clinical, and economic outcomes were described.ResultsA total of 730 154 CHB-diagnosed cases were identified. The prevalence of diagnosed CHB increased from 1.13% in 2010 to 2.43% in 2019, with the highest occurring among those aged 55-64 years (4.76%) and 45-54 years (4.37%) and being higher in men (2.98%) than in women (2.21%). The majority of newly diagnosed CHB patients were 35 years of age or older (86.6%), with a median age of 49 years. After a median follow-up period of 6.42 years, 12.5%, 7.9%, 2.8%, and 0.35% were diagnosed with cirrhosis, decompensated cirrhosis, hepatocellular carcinoma, and liver transplantation respectively. Among 456 706 incident CHB-diagnosed patients, 17.4% had received at least one CHB medication, with the majority taking entecavir (67.9%). Patients with increasing disease severity had higher healthcare resource utilization, and inpatient costs accounted for 48.9%-65.5% of the overall medical cost in different health states.ConclusionDespite the decreasing incidence of newly diagnosed CHB, the prevalence of diagnosed CHB remains high and poses a significant healthcare challenge owing to the high economic burden associated with the complications of CHB.
引用
收藏
页码:2404 / 2414
页数:11
相关论文
共 50 条
[41]   Comorbidity Burden and Treatment Patterns of Psoriasis in Vietnam: Real-World Data from the EXPAND Study [J].
Nguyen, Hao Trong ;
Vu, Anh Tuan ;
Pham, Nhi Thi Uyen ;
Tran, Tu Nguyen Anh ;
Pham, Nguyen Nhat ;
Bui, Huong Thi Thanh ;
Pham, Thuyen Thi ;
Dinh, Vi Thi Thuy ;
Bui, Yen Thi ;
Vu, Thao Thi Phuong .
DERMATOLOGY AND THERAPY, 2023, 13 (12) :3193-3208
[42]   Comorbidity Burden and Treatment Patterns of Psoriasis in Vietnam: Real-World Data from the EXPAND Study [J].
Hao Trong Nguyen ;
Anh Tuan Vu ;
Nhi Thi Uyen Pham ;
Tu Nguyen Anh Tran ;
Nguyen Nhat Pham ;
Huong Thi Thanh Bui ;
Thuyen Thi Pham ;
Vi Thi Thuy Dinh ;
Yen Thi Bui ;
Thao Thi Phuong Vu .
Dermatology and Therapy, 2023, 13 :3193-3208
[43]   Real-world results of direct-acting antivirals use for the treatment of chronic hepatitis C in old patients [J].
El Kassas, Mohamed ;
El Sheemy, Reem ;
Alboraie, Mohamed ;
El Badry, Mohamed ;
Wifi, Mohamed Naguib ;
Youssef, Naglaa ;
Ezzat, Sameera ;
Tahoon, Marwa ;
Abdelsalam, Lobna ;
Abdelhakam, Sara M. ;
Ali-Eldin, Zainab .
EUROPEAN GERIATRIC MEDICINE, 2019, 10 (02) :295-302
[44]   Real-world single-center experience with entecavir and tenofovir disoproxil fumarate in treatment-naive and experienced patients with chronic hepatitis B [J].
Kim, Young Min ;
Shin, Hyun Phil ;
Lee, Joung Il ;
Joo, Kwang Ro ;
Cha, Jae Myung ;
Jeon, Jung Won ;
Yoon, Jin Young ;
Kwak, Min Seob .
SAUDI JOURNAL OF GASTROENTEROLOGY, 2018, 24 (06) :326-335
[45]   Changes in blood lipids in patients with chronic hepatitis B after 48 weeks of tenofovir alafenamide treatment: A prospective real-world clinical study [J].
Zhang, Yeqiong ;
Li, Zhipeng ;
Luo, Qiumin ;
Xu, Wenxiong ;
Wang, Lu ;
Zhu, Shu ;
Peng, Liang ;
Xie, Chan .
ANTIVIRAL THERAPY, 2022, 27 (01)
[46]   Long-Term Real-World Outcomes of Tenofovir Alafenamide in Chronic Hepatitis B: Detailed Analysis of Treatment-Naive and Experienced Patients [J].
Song, Yu-Xuan ;
Song, Guang-Jun ;
Ma, Hui ;
Feng, Bo ;
Xie, Yan-Di .
KOREAN JOURNAL OF GASTROENTEROLOGY, 2025, 85 (01) :64-72
[47]   Combination treatment with sofosbuvir and ribavirin for patients diagnosed with hepatitis C genotype 2: A real-world, single-center study [J].
Choi, Ik Sung ;
Kim, Kwang Min ;
Shim, Sang Goon .
ARAB JOURNAL OF GASTROENTEROLOGY, 2021, 22 (01) :23-27
[48]   Hepatitis B surface antigen loss and sustained viral suppression in Asian chronic hepatitis B patients: A community-based real-world study [J].
Wong, R. J. ;
Nguyen, M. T. ;
Trinh, H. N. ;
Chan, C. ;
Huynh, A. ;
Ly, M. T. ;
Nguyen, H. A. ;
Nguyen, K. K. ;
Torres, S. ;
Yang, J. ;
Liu, B. ;
Garcia, R. T. ;
Bhuket, T. ;
Baden, R. ;
Levitt, B. ;
da Silveira, E. ;
Gish, R. G. .
JOURNAL OF VIRAL HEPATITIS, 2017, 24 (12) :1089-1097
[49]   Evaluation of Real-World Treatment Patterns and Healthcare Resource Utilization in Patients with Chronic Refractory Gout in the United States [J].
Kragh, Nana ;
Worsfold, Andrew ;
Oladapo, Abiola ;
Gao, Emily ;
Sethi, Sakshi ;
Swallow, Elyse .
ADVANCES IN THERAPY, 2025, 42 (07) :3173-3185
[50]   Effectiveness and Safety of Tenofovir Alafenamide in Treatment-Naive and Treatment-Experienced Patients with Chronic Hepatitis B: Results of a Real-World Study from China [J].
Li, Lan-Qing ;
Wang, Fa-Da ;
Zhou, Jing ;
Wang, Meng-Lan ;
Tao, Yachao ;
Chen, En-Qiang .
HEPATITIS MONTHLY, 2023, 23 (01)